A Phase 3 interventional study of extended-release buprenorphine (XR-B) in Opioid Use Disorder, sponsored by Friends Research Institute, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Friends Research Institute, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. — 4 open to participants now, 7 under way, 3 of them phase 3. Opioid-Related Disorders · Friends Research Institute, Inc..
Among the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., this one is the 7th largest by planned enrollment, is one of 5 that started in 2025, is one of 4 in phase 3, and was the 15th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →4 of the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. are open now, in 1 country. Recruiting first, the newest first:
Friends Research Institute, Inc. · Sites in United States
Ages 18+ · Women only
Friends Research Institute, Inc. · Sites in United States
Ages 18+
Friends Research Institute, Inc. · Sites in United States
Ages 18–99
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 235 across the 20 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Friends Research Institute, Inc. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
2 of the studies in Opioid-Related Disorders by Friends Research Institute, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766631Phase 3Friends Research Institute, Inc.Treating Polysubstance Use Using a Novel Digital Technology | 2027-06-30 |
| NCT06573476Friends Research Institute, Inc.Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.
This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.
Aim 1. Compare the effectiveness of XR-B vs. SL-B Aim 2. To calculate the cost to the state and/or jail/city health system of implementing XR-B and SL-B, and determine the relative value, including the costs associated with the interventions in the community, from a county and state-policymaker and societal perspective.
Aim 3. Explore barriers and facilitators to XR-B versus SL-B implementation in jail: (1) dose induction; (2) diversion and procedures for reducing diversion; (3) continuity of care after release or transfer to another facility; (4) staffing (both custody and medical) needs for daily versus XR-B buprenorphine dosing; and (5) patient preference for XR-B versus SL-B.
Primary Outcome. (a) illicit opioid use (i. urine toxicology; ii. self-reported days of opioid use using Timeline Followback; and iii. time to opioid relapse).
Secondary Outcomes. (b) retention in buprenorphine treatment (i. days receiving buprenorphine and ii. time to treatment dropout); (c) other illicit substance use (i. urine toxicology; ii. self-reported days of illicit substance use using Timeline Followback; (d) overdose events (non-fatal and fatal); (e) quality of life (i. physical health; ii. mental health); (f) HIV risk behaviors (i. sexual risk behavior; ii. needle use or sharing); and (g) criminal activity (i. crime days; ii. re-arrest; iii. technical violations; iv. re-incarceration).
Costs. (a) cost to the correctional system; (b) costs associated with community intervention
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone. If they tolerate sl buprenorphine, on day 4 they will be administered an 8 mg dose of BRIXADI on day 5 (if they do not tolerate sl buprenorphine/naloxone we will extend sl dosing). During week two of dosing, they will receive 16 mg dose of BRIXADI will be given, based on the participant's response to the previous dose. During week three of dosing, they will receive a 24 mg dose of BRIXADI. During week four they will be administered a monthly dose of 64mg, 96mg, or 128mg. In all cases, the dose selected will be based on their response to the previous weeks' dose. We will endeavor to get you on the 96 mg or 128 mg monthly dose as there is a lack of opioid blockade data for the 64 mg monthly dose.
Drug: extended-release buprenorphine (XR-B)
Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone.
Drug: extended-release buprenorphine (XR-B)
buprenorphine
Also known as: sublingual buprenorphine (SL-B)
urine toxicology
positive urine drug screen for opioids
Time frame: 12-months
days of opioid use
Number of days since last assessment
Time frame: 12-months
time to opioid relapse
days from release from jail to first relapse event
Time frame: 12-months
retention in buprenorphine treatment
days receiving buprenorphine
Time frame: 6-months
urine toxicology for other illicit substance use
positive urine drug screen
Time frame: 12-months
days of illicit substance use
number of days since last assessment
Time frame: 12-months
overdose events
fatal and non-fatal overdose events
Time frame: 12-months
PROMIS Patient-Reported Outcomes Measurement Information System - physical health
Global physical health score
Time frame: 12-months
PROMIS Patient-Reported Outcomes Measurement Information System - mental health
Global mental health score
Time frame: 12-months
HIV risk behaviors (Risk Assessment Battery, RAB) - sex risk score
sexual risk behavior; Scored 0-18 (higher risk)
Time frame: 12-months
HIV risk behaviors (Risk Assessment Battery, RAB) needle use or sharing score
needle use or sharing; Scored 0-22 (higher risk)
Time frame: 12-months
criminal activity
i. crime days; ii. re-arrest; iii. technical violations; iv. re-incarceration
Time frame: 12-months
Plan to share: Yes — Working on a plan.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jan 2029, 42 months after the start.
Of 31 phase 3 interventional studies under Opioid-Related Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Friends Research Institute, Inc.